An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
Phase of Trial: Phase III
Latest Information Update: 10 Jun 2019
Price : $35 *
At a glance
- Drugs Idalopirdine (Primary) ; Donepezil; Memantine
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms STAR Extension
- Sponsors Lundbeck A/S
- 25 Jul 2017 Status changed from active, no longer recruiting to completed.
- 20 Jun 2017 The trial has been completed in Denmark.
- 31 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Jul 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History